{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:22:09Z","timestamp":1787235729727,"version":"build-2736575974"},"reference-count":42,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID\u00ae at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system.\r\nMaterials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID\u00ae in women over the past decade. \r\nResults: Medicines have a direct antiviral effect on papillomaviruses. Clinical trials have shown that the drugs are safe and effective agents for the treatment of papillomavirus-associated CIN1 and CIN2 in the mode of simultaneous systemic and topical use. The proposed scheme is a promising method of treating class I-II neoplasias in women of reproductive age, as it avoids cervical damage, early and late complications and preserves female reproductive function.\r\nConclusions: PROTEFLAZID\u00ae (drops and suppositories) are safe and effective etiopathogenetic drugs for the systemic and topical treatment of papillomavirusassociated diseases in women. Medicines demonstrate the potential for the prevention of cervical cancer, as they allow organ-preserving treatment in women of reproductive age as a guarantee of future motherhood.<\/jats:p>","DOI":"10.36740\/merkur202504117","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:40:34Z","timestamp":1757418034000},"page":"546","source":"Crossref","is-referenced-by-count":1,"title":["Human papillomavirus: problems and prospects for women\u2019s reproductive health (systematic review)"],"prefix":"10.36740","volume":"53","author":[{"given":"Oleksandr Y.","family":"Hrynevych","sequence":"first","affiliation":[{"name":"LLC \u201eECOFARM\u201d, KYIV, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"ref0","unstructured":"1. Abdiraimova RB, Mambetova ME, Abdurasimova ZA et al. Proteflazid u likuvanni papilomavirusnykh urohenital\u02b9nykh infektsiy. [Proteflazid in the treatment of papillomavirus urogenital infections.]. Visnyk YUK\u00b7HFA \u00abKhabarshysy\u00bb, 2013;1(62): 129-131. (Ukrainian)"},{"key":"ref1","unstructured":"2. Voloshyna NM, Zvantseva ED. Shlyakhy znyzhennya diahnostychnoyi ta likuval\u02b9noyi ahresiyi u patsiyentok z VPL-infektsiyeyu u reproduktyvnomu vitsi. [Ways to reduce diagnostic and therapeutic aggression in patients with HPV infection in reproductive age]. Zdorov\u02b9\u02b9ya zhinky, 2017; 9(125):51-58. (Ukrainian)"},{"key":"ref2","unstructured":"3. Vorobyova LI. Papilomavirusna infektsiya: aktual'na problema suchasnoyi hinekolohiyi. Papillomavirus infection: an actual problem of modern gynecology. Zdorov\u02b9ya zhinky. 2015;3(99):21\u201324. (Ukrainian)"},{"key":"ref3","unstructured":"4. Hodlevs\u02b9ka NA, Starovir AV. Efektyvnist\u02b9 systemnoho ta mistsevoho zastosuvannya preparatu Proteflazid\u00ae u likuvanni patolohiyi shyyky matky, sprychynenoyi papilomavirusnoyu infektsiyeyu. [Efficacy of systemic and local application of the drug Proteflazid\u00ae in the treatment of cervical pathology caused by papillomavirus infection]. Zdorov\u02baya zhinky. 2012;3(69):80-83. (Ukrainian)"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Hodlevs\u02b9ka NA, Starovyer AV. Klinichna efektyvnist\u02b9 mistsevoho zastosuvannya vahinal\u02b9nykh supozytoriyiv Proteflazid\u00ae u likuvanni tservikal\u02b9noyi intraepitelial\u02b9noyi neoplaziyi lehkoho ta pomirnoho stupeniv, zumovlenoyi virusom papilomy lyudyny. [Clinical efficacy of local application of vaginal suppositories Proteflazid\u00ae in the treatment of mild and moderate cervical intraepithelial neoplasia caused by human papillomavirus]. Zdorov\u2019ya zhinky. 2017;2(118):55-60. (Ukrainian) DOI: 10.15574\/hw.2017.118.55","DOI":"10.15574\/HW.2017.118.55"},{"key":"ref5","unstructured":"6. Yehorov OO. Kompleksna diahnostyka peredpukhlynnykh zakhvoryuvan\u02b9 shyyky matky. [Complex diagnostics of precancerous diseases of the cervix]. Zhinochyy likar, 2010;5(31):37-43. (Ukrainian)"},{"key":"ref6","unstructured":"7. Zaporozhan VM, Marichereda VH, Dimcheva LI. Zastosuvannya flavonovykh hlikozydiv u terapiyi henital\u02b9noyi papilomavirusnoyi infektsiyi u zhinok. [Use of flavone glycosides in the treatment of genital papillomavirus infection in women]. Journal of Health Sciences. 2014;4(12):93-104. (Ukrainian)"},{"key":"ref7","unstructured":"8. Zaporozhan VM, Kamins\u02b9kyy VV, Svyntsyts\u02b9kyy VS et al. Natsional\u02b9nyy konsensus shchodo vedennya patsiyentok z tservikal\u02b9nymy intraepitelial\u02b9nymy neoplaziyamy, zumovlenymy papilomavirusnoyu infektsiyeyu. [National consensus on the management of patients with cervical intraepithelial neoplasia caused by papillomavirus infection]. Zdorov\u2019ya zhinky, 2017;7(123):16-24. (Ukrainian)"},{"key":"ref8","unstructured":"9. Rak sheyky matky. [Cancer of the cervix]. WHO. http:\/\/www. who.int\/mediacentre\/factsheets\/fs380\/ru\/ (Russian)"},{"key":"ref9","unstructured":"10. Informatsiyna zapyska VOOZ: Kompleksna profilaktyka raku shyyky matky ta borot\u02b9ba z nym \u2013 zdorove maybutnye dlya divchatok i zhinok. Vsesvitnya orhanizatsiya okhorony zdorov\u02baya. [WHO Information Note: Comprehensive prevention and control of cervical cancer \u2013 a healthy future for girls and women]. World Health Organization. L\u2019IV Com S\u00e0rl, Villarssous-Yens, Switzerland. 2013, p.13. (Ukrainian)"},{"key":"ref10","unstructured":"11. Kamins\u02b9kyy VV, Sukhanova AA, Shal\u02b9ko MN et al. Porivnyal\u02b9na otsinka rezul\u02b9tatyvnosti riznykh skhem zastosuvannya pryrodnykh flavonoyidiv preparatu Proteflazid\u00ae u terapiyi tservikal\u02b9nykh intraepitelial\u02b9nykh neoplaziy (CIN) lehkoho ta pomirnoho stupenya, asotsiyovanykh z henital\u02b9noyu papilomavirusnoyu infektsiyeyu. [Comparative evaluation of the effectiveness of different regimens of natural flavonoids of the drug Proteflazid\u00ae in the treatment of mild and moderate cervical intraepithelial neoplasia (CIN) associated with genital papillomavirus infection]. Zdorov\u2019ya zhinky. 2019;1(137):48-54. (Ukrainian)"},{"key":"ref11","unstructured":"12. Kamins\u02b9kyy VV, Shal\u02b9ko MM, Vorobyova LI et al. PROTEFLAZID\u00ae: spetsyfichna aktyvnist\u02b9 u doklinichnykh doslidzhennyakh, efektyvnist\u02b9 ta bezpeka zastosuvannya u klinichniy praktytsi pry zakhvoryuvannyakh, sprychynenykh virusom papilomy lyudyny (systematychnyy ohlyad). [PROTEFLAZID\u00ae: specific activity in preclinical studies, efficacy and safety of use in clinical practice in diseases caused by human papillomavirus (systematic review)]. Zdorov\u2019ya zhinky. 2015; 3(99):122-132. (Ukrainian)"},{"key":"ref12","unstructured":"13. Kamins\u02b9kyy VV, Shal\u02b9ko MN, Mykhaylov VS et al. Otsinka efektyvnosti preparatu PROTEFLAZID\u00ae pry likuvanni papilomavirusnoyi infektsiyi: meta-analiz rezul\u02b9tativ bahatorichnykh klinichnykh doslidzhen\u02b9. [Evaluation of the effectiveness of the drug PROTEFLAZID\u00ae in the treatment of papillomavirus infection: meta-analysis of the results of long-term clinical studies]. Medychni aspekty zdorov\u2019ya zhinky. 2015;6(92):5-14. (Ukrainian)"},{"key":"ref13","unstructured":"14. Kamins\u02b9kyy VV, Shal\u02b9ko MM, Hrynevych OY. Porivnyal\u02b9na efektyvnist\u02b9 ta bezpeka supozytoriyiv ta krapel\u02b9 Proteflazid u patsiyentok z dysplaziyeyu epiteliyu shyyky matky, obumovlenoyi papilomavirusnoyu infektsiyeyu. [Comparative efficacy and safety of suppositories and drops Proteflazid in patients with cervical epithelial dysplasia caused by papillomavirus infection]. Ukr.Med.Chasopys. 2015;4(108):57-59. (Ukrainian)"},{"key":"ref14","unstructured":"15. Kedrova AH, Podiyetov YUI, Kuznyetsov VV et al. Rol\u02b9 protyvirusnoyi terapiyi v kompleksnomu likuvanni khvorykh na epitelial\u02b9ni dysplaziyi ta preinvazyvnyy rak shyyky matky. [The role of antiviral therapy in the complex treatment of patients with epithelial dysplasia and preinvasive cervical cancer]. Akusherstvo ta hinekolohiya, 2006;6:27-30. (Ukrainian)"},{"key":"ref15","unstructured":"16. Kysel\u02b9ova VI, Krykunova LI, Lyubyna LV. Infikuvannya virusom papilomy lyudyny i prohnoz RSHM. [Infection with human papillomavirus and prognosis of cervical cancer]. Pytannya onkolohiyi. 2010;2:185\u2013187. (Ukrainian)"},{"key":"ref16","unstructured":"17. Kokhanevych YEV. Patolohiya shyyky ta tila matky: kerivnytstvo dlya likariv akusheriv-hinekolohiv, onkolohiv, tsytolohiv, histolohiv, vykladachiv ta studentiv med. in-tiv. [Pathology of the cervix and uterine corpus: a guide for obstetrician-gynecologists, oncologists, cytologists, histologists, teachers and students of medical in- stitutes]. Nizhyn: Hidromaks. 2009, p.350. (Ukrainian)"},{"key":"ref17","unstructured":"18. Mynkyna HN, Manukhin IB, Frank HA. Peredrak shyyky matky. [Cervical precancer]. M.: Aerohrafmedia. 2001, p.112. (Ukrainian)"},{"key":"ref18","unstructured":"19. Rak shyyky matky: symptomy, diahnostyka ta faktory ryzyku. [Cervical cancer: symptoms, diagnosis and risk factors]. 2022. Tsentr hromads\u02b9koho zdorov\u02baya OZ Ukrayiny. https:\/\/phc.org.ua\/news\/rak-shiyki-matki-simptomi-diagnostika-ta-faktori-riziku [Accessed 10 October 2024] (Ukrainian)"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Potapov VO. Rezul\u02b9taty klinichnoyi i molekulyarno-histolohichnoyi otsinky efektyvnosti likars\u02b9koho zasobu PROTEFLAZID\u00ae v likuvanni papilomavirusnoyi infektsiyi u zhinok z tservikal\u02b9noyu intraepitelial\u02b9noyu neoplaziyeyu. [Results of clinical and molecular-histological evaluation of the effectiveness of the drug PROTEFLAZID\u00ae in the treatment of papillomavirus infection in women with cervical intraepithelial neoplasia]. PROTEFLAZID\u00ae: klinichnyy dosvid. Kyiv. 2024. (Ukrainian) DOI: 10.15574\/hw.2024.4(173).514","DOI":"10.15574\/HW.2024.4(173).514"},{"key":"ref20","unstructured":"21. Rak v Ukrayini, 2022-2023.: Zakhvoryuvanist\u02b9, smertnist\u02b9, pokaznyky diyal\u02b9nosti onkolohichnoyi sluzhby. [Cancer in Ukraine, 2022-2023.: Incidence, mortality, indicators of oncological service activity]. Byuleten\u02b9 Natsyonal\u02b9noho kantser-reyestru Ukrayiny. Kyiv. 2024, p.25. (Ukrainian)"},{"key":"ref21","unstructured":"22. Rohovs\u02b9ka SI. Papilomavirusna infektsiya u zhinok ta patolohiya shyyky matky. [Papillomavirus infection in women and cervical pathology]. M. 2008, p.14. (Ukrainian)"},{"key":"ref22","unstructured":"23. Spivak MYA, Rybalko SL, Starosyla DB et al. Otsinka vplyvu flavonoyidvmisnoho preparatu Proteflazid na modeli papiloma virusnoyi infektsiyi in vitro. [Evaluation of the effect of the flavonoid-containing drug Proteflazid on models of papilloma virus infection in vitro]. Dopovidi Natsional\u02b9noyi akademiyi nauk Ukrayiny. 2018;10:103-111. (Ukrainian)"},{"key":"ref23","unstructured":"24. Sukhanova OO, Syrotyns\u02b9ka HI, Sokolova YEI. Osoblyvosti VPL-infektsiyi u zhinok Ukrayiny. [Peculiarities of HPV infection in women of Ukraine]. Akusherstvo. Hinekolohiya. Henetyka, 2016;2(2):12-22. (Ukrainian)"},{"key":"ref24","unstructured":"25. Dovlethanova ER, Prilepskaya VN. Dyferentsiyovanyy pidkhid do likuvannya zakhvoryuvan\u02b9 statevykh orhaniv u zhinok, pov\u2019yazanykh z VPL-infektsiyeyu. [A differentiated approach to the treatment of genital disease in women associated with HPV infection]. Akusherstvo ta Hinekolohiya. 2015;10:118-124. (Ukrainian)"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Gillet E, Meys JF, Verstraelen H et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis. 2011;11:10. doi: 10.1186\/1471-2334-11-10. DOI: 10.1186\/1471-2334-11-10","DOI":"10.1186\/1471-2334-11-10"},{"key":"ref26","unstructured":"27. Heryak S, Petrenko N, Dobrianska V. Prevention of perinatal complications in pregnant women with chronic papillomavirus infection. Pol Merkur Lek, 2020;XLVIII (285):157-161."},{"key":"ref27","unstructured":"28. ICO\/IARC Information Centre on HPV and Cancer. 2018."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322\/caac.20107. DOI: 10.3322\/caac.20107","DOI":"10.3322\/caac.20107"},{"key":"ref29","unstructured":"30. Kaminsky V, Chernyshov V, Grynevych O et al. Proteflazid\u00ae and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections. Pol Merkur Lek, 2017;XLII(249):51-56."},{"key":"ref30","unstructured":"31. Kuzmenko-Chornovil OV, Makogonov IO, Vergun AR et al. Dosvid likuvannya patsiyentok reproduktyvnoho viku z khronichnym tservitsytom ta papilomavirusnoyu infektsiyeyu. [Experience of treating reproductive age patients with chronic cervicitis and papillomavirus infection]. International scientific journal \u201eInternauka\u201d. 2020;5(85):16-21. (Ukrainian)"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Mayrand MH, Duarte-Franco E, Rodrigues I \u0435t al. Human papillomavirus DNA versus Papanicolaou screening tests cervical. N. Engl. J. Med. 2007;357(16):1579-1588. doi: 10.1056\/NEJMoa071430. DOI: 10.1056\/nejmoa071430","DOI":"10.1056\/NEJMoa071430"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. McCredie MR, Sharples KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervicalintraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-34. doi: 10.1016\/S1470-2045(08)70103-7. DOI: 10.1016\/S1470-2045(08)70103-7","DOI":"10.1016\/S1470-2045(08)70103-7"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Moscicki AB, Yi Ma, Jonte Ja et al. The role of sexual behavior and HPV persistence in predicting repeated infections with new HPV types. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2055-65. doi: 10.1158\/1055-9965.EPI-10-0394. DOI: 10.1158\/1055-9965.EPI-10-0394","DOI":"10.1158\/1055-9965.EPI-10-0394"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006:24(3):S3\/42-51. doi: 10.1016\/j.vaccine. 2006.06.018. DOI: 10.1016\/j.vaccine.2006.06.018","DOI":"10.1016\/j.vaccine.2006.06.018"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. Oster AG. Natural history of CIN: a critical review. In. J. Gynecol. Pathol.,1993;12:186-192. DOI: 10.1097\/00004347-199304000-00018","DOI":"10.1097\/00004347-199304000-00018"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Porras C, Rodrigues SC, Hildeshein A et al. Human Papillomavirus Types dy Age in Cervical Cancer Precursors: Predoinance of Human Papillomavirus 16 in Young Women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):863-5. doi: 10.1158\/1055-9965.EPI-08-0951. DOI: 10.1158\/1055-9965.epi-08-0951","DOI":"10.1158\/1055-9965.EPI-08-0951"},{"key":"ref37","unstructured":"38. Prilepskaya VN, Nazarova NM, Mzarelua GM et al. Zakhvoryuvannya shyyky matky, asotsiyovani z VPL \u2013 nove v diahnostytsi. [HPV associated cervical disease \u2013 new in diagnostics]. Akusherstvo ta hinekolohiya. 2015;8:20-26. (Ukrainian)"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overallresults of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335(7609):28-38. doi: 10.1136\/bmj.39196.740995.BE. DOI: 10.1136\/bmj.39196.740995.be","DOI":"10.1136\/bmj.39196.740995.BE"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445(1-2):138-168. doi: 10.1016\/j.virol.2013.04.013. DOI: 10.1016\/j.virol.2013.04.013","DOI":"10.1016\/j.virol.2013.04.013"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41. Vergun A, Makahonov I, Kuzmenko-Chornovil O et al. Complex (integrated) treatment of chronic cervicitis associated with papillomavirus infection in reproductive age patients. Innovative Solutions in Modern Science. 2020;2(38):64\u201380. doi: 10.26886\/2414-634X.2(38)2020.6. DOI: 10.26886\/2414-634X.2(38)2020.6","DOI":"10.26886\/2414-634X.2(38)2020.6"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42. Wang X, Wang HK, Li Y et al. MicroRNAs are biomarkers of oncogenic human papillomavirus infections. Proc. Natl. Acad. Sci. USA. 2014;111(11):4262-4267. doi: 10.1073\/pnas.1401430111. DOI: 10.1073\/pnas.1401430111","DOI":"10.1073\/pnas.1401430111"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:39:48Z","timestamp":1784018388000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i4.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202504117","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}